374 related articles for article (PubMed ID: 19648160)
21. Galectin-3: a modifiable risk factor in heart failure.
de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
[TBL] [Abstract][Full Text] [Related]
22. Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure.
Moorjani N; Westaby S; Narula J; Catarino PA; Brittin R; Kemp TJ; Narula N; Sugden PH
Am J Cardiol; 2009 May; 103(9):1261-8. PubMed ID: 19406269
[TBL] [Abstract][Full Text] [Related]
23. The cellular and physiologic effects of beta blockers in heart failure.
Sabbah HN
Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
[TBL] [Abstract][Full Text] [Related]
24. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
Milting H; Ellinghaus P; Seewald M; Cakar H; Bohms B; Kassner A; Körfer R; Klein M; Krahn T; Kruska L; El Banayosy A; Kramer F
J Heart Lung Transplant; 2008 Jun; 27(6):589-96. PubMed ID: 18503956
[TBL] [Abstract][Full Text] [Related]
25. Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis.
Li GH; Shi Y; Chen Y; Sun M; Sader S; Maekawa Y; Arab S; Dawood F; Chen M; De Couto G; Liu Y; Fukuoka M; Yang S; Da Shi M; Kirshenbaum LA; McCulloch CA; Liu P
Circ Res; 2009 Apr; 104(7):896-904. PubMed ID: 19246681
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
27. Impact of obesity on the risk of heart failure and its prognosis.
Artham SM; Lavie CJ; Patel HM; Ventura HO
J Cardiometab Syndr; 2008; 3(3):155-61. PubMed ID: 18983332
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of galectin-3 is associated with progression of human breast cancer.
Castronovo V; Van Den Brûle FA; Jackers P; Clausse N; Liu FT; Gillet C; Sobel ME
J Pathol; 1996 May; 179(1):43-8. PubMed ID: 8691344
[TBL] [Abstract][Full Text] [Related]
29. Galectin-3 in cardiac remodeling and heart failure.
de Boer RA; Yu L; van Veldhuisen DJ
Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
[TBL] [Abstract][Full Text] [Related]
30. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure.
Tarquini R; Guerra CT; Porciani MC; Michelucci A; Padeletti M; Ricciardi G; Chiostri M; Jelic S; Padeletti L
Cardiol J; 2009; 16(6):545-52. PubMed ID: 19950091
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis.
Htwe TT; Karim N; Wong J; Jahanfar S; Mansur MA
Singapore Med J; 2010 Nov; 51(11):856-9. PubMed ID: 21140111
[TBL] [Abstract][Full Text] [Related]
32. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7.
Cludts S; Decaestecker C; Mahillon V; Chevalier D; Kaltner H; André S; Remmelink M; Leroy X; Gabius HJ; Saussez S
Anticancer Res; 2009 Dec; 29(12):4933-40. PubMed ID: 20044599
[TBL] [Abstract][Full Text] [Related]
33. Roles of galectin-3 in immune responses.
Chen HY; Liu FT; Yang RY
Arch Immunol Ther Exp (Warsz); 2005; 53(6):497-504. PubMed ID: 16407782
[TBL] [Abstract][Full Text] [Related]
34. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
[TBL] [Abstract][Full Text] [Related]
35. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II.
Szöke T; Kayser K; Trojan I; Kayser G; Furak J; Tiszlavicz L; Baumhäkel JD; Gabius HJ
Eur J Cardiothorac Surg; 2007 May; 31(5):783-7. PubMed ID: 17369045
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
37. The role of galectins in the initiation, amplification and resolution of the inflammatory response.
Rubinstein N; Ilarregui JM; Toscano MA; Rabinovich GA
Tissue Antigens; 2004 Jul; 64(1):1-12. PubMed ID: 15191517
[TBL] [Abstract][Full Text] [Related]
38. Heart failure: update on treatment and prognosis.
Futterman LG; Lemberg L
Am J Crit Care; 2001 Jul; 10(4):285-93. PubMed ID: 11432217
[TBL] [Abstract][Full Text] [Related]
39. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.
Sciarretta S; Paneni F; Palano F; Chin D; Tocci G; Rubattu S; Volpe M
Clin Sci (Lond); 2009 Mar; 116(6):467-77. PubMed ID: 19200056
[TBL] [Abstract][Full Text] [Related]
40. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project.
Kosiborod M; Curtis JP; Wang Y; Smith GL; Masoudi FA; Foody JM; Havranek EP; Krumholz HM
Arch Intern Med; 2005 Oct; 165(19):2237-44. PubMed ID: 16246989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
